News
Zacks.com on MSN1d
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...
Zacks.com on MSN13d
Will Increased Expenses Affect Bristol Myers' Performance?Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
Zacks Investment Research on MSN4d
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...
Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.
Read about BioNTech SE ADR (BNTX:XNAS) stock and today's latest news and financial updates.
Zacks Investment Research on MSN22d
SMMT Stock Gains on Rumored Licensing Talks With AstraZenecaShares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...
Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...
Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...
Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback